ISSN 1016-5169 | E-ISSN 1308-4488
Archives of the Turkish Society of Cardiology
RE-LY study: subgroup analyses and reflections on clinical guidelines [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2013; 41(4): 15-18

RE-LY study: subgroup analyses and reflections on clinical guidelines

Murat Özdemir
Gazi University Faculty of Medicine, Department of Cardiology, Ankara, Turkey

Dabigatran is a direct thrombin inhibitor that has been shown in the RE-LY trial to be either noninferior (110 mg b.i.d) or superior (150 mg b.i.d) to warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and at least one risk factor for stroke. This article summarizes selected subgroup analyses of the RE-LY trial and their reflections, if any, on clinical guidelines.


How to cite this article
Murat Özdemir. RE-LY study: subgroup analyses and reflections on clinical guidelines. Turk Kardiyol Dern Ars. 2013; 41(4): 15-18

Corresponding Author: Murat Özdemir, Türkiye
Manuscript Language: Turkish


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.